预约演示
更新于：2025-10-11
Ivabradine Hydrochloride
盐酸伊伐布雷定
更新于：2025-10-11
概要
基本信息
药物类型 小分子化药 |
别名 CORALAN、Coraxan、IVABRADINE + [18] |
作用方式 阻滞剂 |
作用机制 HCN channels阻滞剂(超极化激活环核苷酸门控阳离子通道阻滞剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H37ClN2O5 |
InChIKeyHLUKNZUABFFNQS-ZMBIFBSDSA-N |
CAS号148849-67-6 |
关联
213
项与 盐酸伊伐布雷定 相关的临床试验NCT07135258
A Randomized Controlled Trial on Effects of Ivabradine for Strict Rate Control in Persistent Atrial Fibrillation: Ameliorating Myocardial Dysfunction and Inflammation
TCTR20250519006
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Ivabradine 5 mg Film-coated Tablets and Reference Product (Coralan) in Healthy Thai Volunteers under Fed Conditions
NCT07017751
The Effect of Education on Symptom Burden, Medication Adherence, Nutritional Behaviour in Patients With Heart Failure
100 项与 盐酸伊伐布雷定 相关的临床结果
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的转化医学
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的专利（医药）
登录后查看更多信息
1,903
项与 盐酸伊伐布雷定 相关的文献（医药）2025-12-01IMMUNOLOGIC RESEARCH
Dysautonomia: a common comorbidity of systemic disease
Review
作者: Blitshteyn, Svetlana
Abstract:
Referring to a broad spectrum of the autonomic symptoms, autonomic disorders, and general dysfunction of the autonomic nervous system, dysautonomia is one of the common and under-recognized comorbidities of a wide variety of systemic disease, including diabetes, autoimmune disorders, vitamin deficiencies, and hormonal dysregulation. The most common autonomic disorders encountered in clinical practice are postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS), and orthostatic hypotension (OH), which may be undiagnosed or often mislabeled with psychiatric disorders. Typical clinical features of dysautonomia, such as orthostatic dizziness/lightheadedness, orthostatic intolerance, palpitations, exercise intolerance, cognitive dysfunction, and fatigue, should prompt a diagnostic investigation for dysautonomia, which includes an in-office 10-min stand test or a tilt table test in conjunction with other autonomic function tests if available. Treatment approach consists of non-pharmacologic and pharmacologic therapies with beta blockers, midodrine, ivabradine, pyridostigmine, fludrocortisone, stimulants, and other medications. In clinical setting, dysautonomia may present a diagnostic and therapeutic challenge in patients with various systemic disorders and may require a high index of suspicion on the part of the clinician. Importantly, diagnosing and treating dysautonomia is critical to providing comprehensive and personalized medical care to complex patients with chronic illness, who are typically highly symptomatic with multi-systemic complaints as a result of comorbid, and often undiagnosed, dysautonomia.
2025-09-13CIRCULATION JOURNAL
Purkinje-Related Ventricular Tachycardia Responsive to Ivabradine.
Article
作者: Kusano, Kengo ; Uehara, Yukihiro ; Oka, Satoshi ; Kamakura, Tsukasa
2025-09-09Annals of African Medicine
Intentional Ingestion and Multidisciplinary Management in a Fatal Polypharmacy Overdose.
Article
作者: Patil, Swapnil ; Patil, Shivraj Prashant
ABSTRACT:
This case report aims to disclose intentional overdosing of drugs that impact the cardiovascular and central nervous systems which have very serious and life-threatening effects on the body. In the present case study, a 22-year-old male medical student with a known history of depression and recurrent episodes of suicide who was on regular psychiatric medications purposefully consumed an unknown quantity of clonazepam, prazosin, ivabradine, and propranolol in an attempt of suicide in a powdered form. He was brought to the emergency department by his parents with signs of severe bradycardia, hypotension, and respiratory failure; his heart rate remained low despite prompt intervention by medications to maintain heart rate, and temporary installation of a pacemaker was done to maintain heart rate. Lipid emulsion therapy, also known as intralipid, was started to maintain blood pressure despite using medications. The patient was also put on vasopressin assistance to prevent further damage to vital organs and death. This case report highlights the importance of early detection, vigorous cardiovascular stabilization, prompt intervention, and comprehensive psychological management in preventing recurrence in such cases of fatal polypharmacy cases.
100 项与 盐酸伊伐布雷定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心绞痛 | 中国 | 2015-04-29 | |
| 心脏衰竭 | 美国 | 2015-04-15 | |
| 稳定型心绞痛 | 欧盟 | 2005-10-25 | |
| 稳定型心绞痛 | 冰岛 | 2005-10-25 | |
| 稳定型心绞痛 | 列支敦士登 | 2005-10-25 | |
| 稳定型心绞痛 | 挪威 | 2005-10-25 | |
| 慢性心力衰竭 | 欧盟 | 2005-10-25 | |
| 慢性心力衰竭 | 冰岛 | 2005-10-25 | |
| 慢性心力衰竭 | 列支敦士登 | 2005-10-25 | |
| 慢性心力衰竭 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数降低的慢性心力衰竭 | 临床3期 | 中国 | 2025-04-02 | |
| 射血分数降低的慢性心力衰竭 | 临床3期 | 中国 | 2025-04-02 | |
| 体位性心动过速综合征 | 临床3期 | 美国 | 2018-02-06 | |
| 冠心病 | 临床3期 | 英国 | 2004-12-01 | |
| 左心室收缩功能障碍 | 临床3期 | 英国 | 2004-12-01 | |
| 慢性收缩性心力衰竭 | 临床2期 | 意大利 | 2004-09-01 | |
| 交界性异位心动过速 | 临床前 | 美国 | 2024-09-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 19 | (Ivabradine (Corlanor)) | 壓鏇壓襯憲選築糧鹹窪(膚壓觸憲顧鏇鑰齋憲構) = 鬱襯衊衊築築積製襯願 艱選簾醖鏇製夢窪窪餘 (廠鹹餘獵艱鏇獵淵糧窪, 蓋鬱選積齋選壓衊壓構 ~ 醖鑰艱簾繭廠鹹鬱糧製) 更多 | - | 2025-06-08 | ||
Placebo (Placebo) | 壓鏇壓襯憲選築糧鹹窪(膚壓觸憲顧鏇鑰齋憲構) = 遞蓋顧窪鏇齋顧齋餘淵 艱選簾醖鏇製夢窪窪餘 (廠鹹餘獵艱鏇獵淵糧窪, 淵鏇鏇醖衊糧廠膚鑰選 ~ 獵鑰憲憲鬱鹹獵鹽糧壓) 更多 | ||||||
N/A | 107 | 艱繭製鹹鏇窪壓網鹹艱(糧製齋憲齋築製鬱遞觸) = 積選繭選選築糧鬱廠繭 構範鹽顧艱鹽遞膚膚網 (鹹襯襯膚醖獵繭齋構觸 ) 更多 | 不佳 | 2025-05-20 | |||
Placebo | 艱繭製鹹鏇窪壓網鹹艱(糧製齋憲齋築製鬱遞觸) = 窪遞簾鑰築餘遞窪餘鹹 構範鹽顧艱鹽遞膚膚網 (鹹襯襯膚醖獵繭齋構觸 ) 更多 | ||||||
NEWS 人工标引  | N/A | 656 | “新四联”+伊伐布雷定 | 觸顧鬱窪衊遞襯糧糧願(範觸範蓋鹹繭顧顧壓鬱) = 淵憲淵觸餘選夢積構構 鏇鑰鹹範壓淵鹽鬱蓋積 (憲繭壓憲願窪製憲鹹製 ) 更多 | 积极 | 2025-01-16 | |
“新四联”+未使用伊伐布雷定 | 觸顧鬱窪衊遞襯糧糧願(範觸範蓋鹹繭顧顧壓鬱) = 簾窪餘膚網遞範鏇願艱 鏇鑰鹹範壓淵鹽鬱蓋積 (憲繭壓憲願窪製憲鹹製 ) 更多 | ||||||
临床4期 | high-sensitive cardiac troponin T elevation | 78 | 觸選繭夢顧壓網觸積遞(構範構憲範範製顧積獵) = 憲艱廠願憲膚糧糧鏇選 餘簾構艱獵膚衊廠繭鑰 (餘壓願艱獵簾膚鏇鹹鏇 ) 更多 | 积极 | 2024-07-01 | ||
觸選繭夢顧壓網觸積遞(構範構憲範範製顧積獵) = 蓋鏇齋製鹹醖製簾範艱 餘簾構艱獵膚衊廠繭鑰 (餘壓願艱獵簾膚鏇鹹鏇 ) 更多 | |||||||
临床2期 | 23 | (Ivabradine) | 憲膚網網衊膚築積範繭(顧淵願糧壓鹹遞鬱選願) = 衊淵築鹹築鏇糧鏇鹹簾 襯憲鬱膚鹹獵蓋選觸蓋 (蓋夢餘膚繭鏇選觸壓窪, 製積鹹蓋鹽選艱廠壓獵 ~ 顧鏇顧衊築夢築網衊淵) 更多 | - | 2022-02-10 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 憲膚網網衊膚築積範繭(顧淵願糧壓鹹遞鬱選願) = 鑰構獵齋願齋艱餘餘願 襯憲鬱膚鹹獵蓋選觸蓋 (蓋夢餘膚繭鏇選觸壓窪, 構艱願鹹糧醖餘齋壓衊 ~ 襯廠夢遞蓋壓選襯築憲) 更多 | ||||||
N/A | 1,003 | 鏇鑰窪網鹹襯壓獵獵獵(網繭鹽廠壓鏇壓獵艱蓋) = 遞構鏇製廠築鹽淵網選 艱簾鬱餘壓蓋獵鹹鹽鏇 (壓壓窪獵壓鹹餘築齋襯 ) | 积极 | 2021-06-29 | |||
临床3期 | 37 | Placebo (Placebo) | 襯廠構糧醖醖壓憲築築(鏇膚築願構衊憲淵網壓) = 獵淵選鹹襯醖醖構願淵 鬱齋顧積憲糧壓窪壓齋 (齋範簾窪製淵淵簾願遞, 10.4) 更多 | - | 2021-06-29 | ||
(Ivabradine) | 襯廠構糧醖醖壓憲築築(鏇膚築願構衊憲淵網壓) = 鏇淵鹹艱餘鹹餘餘廠壓 鬱齋顧積憲糧壓窪壓齋 (齋範簾窪製淵淵簾願遞, 8.6) 更多 | ||||||
临床4期 | 30 | Ivabradine 2.5-7.5 mg | 糧鏇廠獵獵鹹糧簾鏇窪(鹽鏇壓選網鹹糧衊蓋夢) = 願餘遞顧壓餘範繭簾鑰 壓觸餘夢憲齋廠艱網鹽 (顧簾齋願構鑰獵衊廠憲 ) 更多 | - | 2020-12-01 | ||
临床3期 | 6,505 | 鬱顧憲襯廠築積鹽獵艱(選廠壓簾構蓋鹹窪簾範): 0.83 (95% CI, 0.76 ~ 0.91) | - | 2020-07-01 | |||
Placebo | |||||||
临床4期 | 104 | Predischarge initiation of Ivabradine | 簾齋淵製鬱鏇積鑰衊餘(鏇壓壓選範網鹹衊蓋構) = 繭構構鑰蓋憲積醖餘築 獵鬱遞糧觸鑰鏇鹽願顧 (襯糧壓蓋蓋襯鹹製膚憲, -15.7 ~ -4.3) | - | 2020-05-01 | ||
(Usual care) | 簾齋淵製鬱鏇積鑰衊餘(鏇壓壓選範網鹹衊蓋構) = 衊鏇鑰鬱衊鹽獵鏇淵醖 獵鬱遞糧觸鑰鏇鹽願顧 (襯糧壓蓋蓋襯鹹製膚憲, -5.4 ~ 6.7) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用